A company called Efferon is rewriting the survival odds for children battling sepsis. According to TechCrunch, it has just earned a spot at TechCrunch Disrupt 2026's Startup Battlefield 200.
Sepsis, an acute inflammatory response to infection, kills roughly 3 million children under five annually. Efferon's founders saw the gap and filled it with science.
The blood purification is the core innovation. When antibiotics fail and a child's immune system goes haywire, toxins accumulate and organ failure follows. TechCrunch reports that Efferon's absorber technology removes both endotoxins and cytokines simultaneously, a dual-action approach that competitors have not matched. Co-founder and CEO Dima Romashin frames it this way: "sepsis is like a fire with both flames and smoke. Everyone else tackles one. Efferon tackles both."
Efferon NEO is the pediatric-specific device. Children are not just smaller adults, their blood volume is drastically lower, meaning off-the-shelf solutions do not work. Efferon engineered the device from the ground up for tiny bodies, and in April 2026, it became the first multimodal blood purification device for pediatric sepsis to earn a CE mark (Europe's FDA equivalent).
The rollout is already global. According to TechCrunch, Efferon NEO is in use across 30 countries, European hospitals, Saudi Arabia, Thailand. The company is on track to hit $2 million in annualized revenue by year-end, with FDA approval on the horizon.
The founding story matters. The technology was born in Moscow State University labs, developed by scientists who identified a problem that venture capital was not addressing. Romashin, a serial entrepreneur, stepped in to commercialize it.
Romashin measures success not in the speed of growth but in outcomes: every child who gets to go home. In a startup ecosystem focused on valuations and scaling curves, that standard stands apart.
